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Introduction
Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer that is frequently lethal (1) . Most MCCs harbor Merkel cell polyomavirus (MCPyV) DNA, which is involved in the molecular pathogenesis of the disease (2) (3) (4) . MCC usually manifests in the elderly and is sometimes associated with immunosuppressive diseases or medications (5) (6) (7) (8) (9) . Individuals with MCPyV infection-related MCC may have more favorable outcome compared to those with MCPyV-negative cancer. Presence of tumor infiltrating lymphocytes (TILs), especially of cytotoxic T cells, is associated with favorable prognosis in a number of human cancers (3, 4, 10, 11) . MCPyV-negative MCCs express p53 and harbor TP53 gene mutations more frequently than MCPyV DNA-positive carcinomas (12) .
The immune system has likely a role in the genesis and progression of many cancers, and the type of immune system activation may also be associated with patient outcome (13) (14) (15) (16) (17) (18) . Tumor infiltrating monocytes have different roles depending on the macrophage lineage of differentiation in the target tissue. M1 macrophages activate the immune response against malignant or infected cells, whereas M2 macrophages are anti-inflammatory and downregulate M1-mediated immune response, and promote angiogenesis and tissue remodeling (18) . Tumor-associated macrophages often resemble M2 macrophages and may induce and sustain cancer growth, invasion, and tumor angiogenesis by secreting growth factors and other mediators into the tumor microenviroment (19, 20) .
The effect of different types of immune cells on outcome is of particular interest in MCC, since these tumors can be divided into viral infection-associated and non-associated tumors. MCC may rarely (< 2%) regress spontaneously or following mechanical or chemical irritation suggesting a potential therapeutic role for the immune system-modulating approaches (21) (22) (23) (24) (25) (26) . Presence of lymphocytic infiltration (27, 28) and intratumoral CD8+ lymphocytes (cytotoxic lymphocytes) (29) have been reported to be associated with favorable prognosis in MCC, but the influence of other immune cell subsets on the clinical 
Patients and Methods

Patients
Individuals diagnosed with MCC in Finland between January 1, 1979 and October 24, 2004 were identified from the files of the Finnish Cancer Registry that covers virtually all cancers diagnosed in Finland (30) and were included in this retrospective, nationwide, population-based cohort study (4) . We excluded from the 207 subjects thus identified those who had no clinical data (N = 16) or no archival tumor tissue available (N = 37), subjects whose diagnosis could not be confirmed at histopathological review (N = 13) or whose tumor site was unknown (N = 8), and individuals whose tumor MCPyV infection status or CD3 expression could not be analyzed due to inadequate tissue sample quality (N = 17). The remaining 116 subjects form the final study cohort (Fig. 1) . The diagnosis of MCC was confirmed using immunohistochemistry (4, 12) . Tumor histology was classified according to removed at surgery in all cases, and 17 (14.7%) subjects received postoperative radiotherapy. The study was approved by an institutional review board, and a permission to use tumor tissue for research purposes was granted by the Ministry of Social Affairs and Health of Finland.
Identification of MCPyV DNA
Presence of MCPyV DNA was detected using quantitative polymerase chain reaction (qPCR). In brief, genomic DNA was extracted from tumor tissue sections, and the ratio of MCPyV DNA to a reference gene (protein tyrosine phosphatase gamma receptor, PTPRG) DNA was assessed using qPCR, hydrolysis probes and a LightCycler 480 instrument (Roche Diagnostics GmbH, Mannheim, Germany) as described elsewhere (4) . Samples where the MCPyV DNA to PTPRG DNA ratio was smaller than 0.1 were considered MCPyV infection-negative (12) .
Immunohistochemistry
Expression of MCPyV large T antigen (LTA), Ki-67, retinoblastoma (RB) protein, phospho-RB, p53, cyclin D1, cyclin E, p21, p27, and CLEVER-1 was analyzed using immunohistochemistry (12, 33) .
To evaluate expression of immune cell antigens using immunohistochemistry, 5 µm tumor sections were cut on SuperFrost+ slides (Menzel-Gläser, Germany), deparaffinized in xylene and rehydrated through a decreasing ethanol gradient. Endogenous peroxidase activity was blocked by incubating the sections in 3% hydrogen peroxide for 30 minutes (for CD4-staining, in 0.5% H 2 O 2 in methanol for 10 minutes). Heat-induced epitope retrieval was carried out in sodium citrate (10 mM, pH 6.0) using an autoclave (120ºC for 2 minutes)
Research. following the manufacturer's protocol. CD3 and CD68 expression were detected simultaneously using a double immunohistochemical labeling technique. In brief, after antigen retrieval the slides were incubated for 20 minutes with normal horse blocking serum (immPRESS Anti-mouse Ig Polymer detection kit, Vector Laboratories). CD68 antibody was diluted in horse blocking serum, incubated on slides for 30 minutes, and detected using an immPRESS anti-mouse reagent and a NovaRED Peroxidase Substrate Kit (SK-4800, Vector Laboratories; 10 minutes at room temperature). The slides were incubated again in horse stained cells located in the stromal tissue surrounding the tumor, in necrotic areas of the tumor, or at or inside tumor blood vessels were excluded. Morphologically tumor infiltrating macrophages were frequently multinuclear, and the nuclei were lobulated (Fig. 2) . Their cytoplasm was abundant, and in some cases contained dark dots, resembling apoptotic bodies. When assessing the numbers of natural killer cells, small CD16 expressing cells with dense cytoplasm were considered to represent natural killer cells and were counted, whereas large, often multinuclear CD16 expressing cells with abundant cytoplasm were considered macrophages and were not counted. All cell counts were done blinded to the clinicopathological or survival data.
Statistical methods
Continuous distributions were compared using the Mann-Whitney's U test or the Kruskal-Wallis test, and their correlations were assessed using the Spearman´s rank correlation test. Overall survival was calculated from the date of the diagnosis to the date of death due to any cause censoring subjects who were alive at the time of data collection.
MCC-specific survival was calculated from the date of the diagnosis to the date of death considered to be caused by MCC censoring subjects who were alive or who died from another cause or from an unknown cause. Survival between the groups was compared using the Kaplan-Meier life-table method and an unadjusted Cox proportional hazards model; the log-rank test was used to confirm the robustness of the analysis. Multivariable survival analyses were done using the Cox proportional hazards model. Proportional hazard assumptions for covariates were evaluated by examining the log-minus-log plots before their entry into the Cox proportional hazards model. All P values are 2-sided and not adjusted for multiple testing. Table 1 ). The results remained largely similar when the associations between the tumor immune cell counts and tumor MCPyV LTA expression were examined, except that a higher number of CD4+ cells was found in MCPyV LTA-positive tumors as compared MCPyV LTA-negative cancers (median, 3.9 vs. 2.3 per 1 HPF, respectively; P = 0.008) and the association between high CD3+ cell counts and MCPyV infection became more evident (median, 5.9/HPF vs. 2.7/HPF, P < 0.001), whereas the association between small CD16+ cells and MCPyV LTA was no longer statistically significant (median, 1.9/HPF vs. 1.0/HPF, P = 0.125). A high tumor MCPyV DNA copy number was associated with a high tumor CD4+ leukocyte count (P = 0.010) and tended to be associated with a high CD8+ and CD16+ cell count (P = 0.071 and 0.064, respectively), whereas no association was found between the MCPyV DNA copy number and the counts of CD3+, CD68+, FoxP3+, or CD163+ cells (each P > 0.10). CLEVER1-positive tumor infiltrating macrophages were rare and were identified only in 5 tumors (median, 0/HPF; range, 0 to 0.67/HPF), although they were frequently present in the tissues that surrounded the tumors. 
Tumor infiltrating leukocytes and cancer features
None of the leukocyte antigens examined (CD3, CD8, CD4, FoxP3, CD16, CD68, CD163) was significantly associated with gender, the median age at presentation, tumor site, or the tumor proliferation rate as assessed with Ki-67 expression, phospho-RB expression, or with tumor cyclin E or cyclin D1 expression. MCCs with a higher than the median number of CD3+ cells were more often classified as stage I or stage II cancers as compared to tumors with a lower than the median number of CD3 cells (i.e. they gave less frequently rise to either nodal or distant metastases at the time of the diagnosis, P = 0.006, Table 2 ). High counts of CD8, FoxP3, and CD163 expressing cells were associated with a larger than the median tumor size at the time of the diagnosis (Table 2 and Supplementary Table 2 ). High counts of CD3+, CD4+, and FoxP3+ cells were associated with tumor RB expression, and high counts of CD16-positive leukocytes with phospho-RB expression, whereas tumor p53 expression was associated with low counts of CD3, CD8, and FoxP3 expressing cells.
Tumors with high counts of CD3 expressing cells stained frequently positive for p27, and tumors with high counts of small CD16 expressing cells for p21.
Survival analyses
The median age at the time of the diagnosis was 79 years, and 91 (78.4%) out of the 116 subjects were followed up to death. The median follow-up time of the subjects alive was 11.0 years (range, 5.1-22.5 years). MCC was considered to be the cause of death in 26 (28.6%) cases, a competing cause in 48 (52.7%), and in 17 (18.7%) cases the cause of death was not specified or was unknown. 2C ). None of the subjects whose tumor had the CD3+ count within the highest quartile died from MCC (Fig. 2D) . A tumor CD8 count within the lowest quartile was associated with poor survival (Fig. 2E) , a high FoxP3+ cell count with favorable survival (Fig. 2F) , whereas CD4, CD16, CD68, or CD163 cell counts were not significantly associated with survival. The results remained similar when the 5 individuals who had distant metastases at the time of the diagnosis were excluded from the analyses.
A small CD8+/CD4+ ratio < 0.38 or a small FoXP3+/CD4+ ratio < 0.25 were associated with poor overall survival (HR = 2.07, 95% CI = 1.22 to 3.51, P = 0.007; and HR = 2.29, 95% CI = 1.35 to 3.88, P = 0.002, tested the lowest quartile vs. the rest, respectively), whereas the CD8+/FoxP3 ratio was not associated with survival (P = 0.743). In a stratified univariate survival analysis subjects who had a higher than the median tumor CD3 count and MCPyV DNA-positive cancer had the best outcome (Fig. 3E) .
Research. 
Similarly, subjects who had intratumoral CD8+ count above the threshold for the lowest quartile (> 1.0/HPF) and MCPyV DNA-positive tumor survived longer as compared to subjects with MCPyV DNA-negative cancer or those with a low tumor CD8 cell count (Fig.   3F ). Subjects with MCPyV DNA-positive cancer and higher than the median tumor FoxP3+ cell count survived longer than the rest of the subjects (HR = 1.88; 95% CI = 1.08 to 3.27; P = 0.026). Survival analyses corresponding to those shown in Figures 2 and 3 Since age at diagnosis was a strong prognostic factor for death in this elderly patient group, we performed a further multivariate analysis deleting age from the covariates tested.
In this analysis a low tumor CD3 count remained a significant prognostic factor for unfavorable survival (HR = 1.91, 95% CI = 1.21 to 3.01, P = 0.005) together with presence of nodal metastases (HR = 2.96, 95% CI = 1.46 to 6.01, P = 0.003), absence of tumor MCPyV DNA (HR = 1.93, 95% CI = 1.20 to 3.10, P = 0.007), and male gender (HR = 1.78, 95% CI = 1.10 to 2.87, P = 0.018). The reasons why patients with high intratumoral immune cell counts have favorable survival as compared to those with low counts remain speculative, but the present study provides some clues. None of the leukocyte antigens examined was associated with the tumor cell proliferation rate when assessed by immunostaining for Ki-67, phospho-RB, cyclin E, or cyclin D1, and high CD8+, FoxP3+, and CD163+ cell counts were associated with a large primary tumor size, whereas MCCs with higher than the median number of CD3+ cells had infrequently given rise to metastases at the time of the diagnosis. Taken together, these 
Discussion
We found that high numbers of several types of tumor infiltrating leukocytes, T cells (CD3+), cytotoxic T cells (CD8+), helper T cells (CD4+), regulatory T cells (FoxP3+
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